New EU Filings

 
• By Neena Brizmohun

Acoramidis, AstraZeneca/BridgeBio Pharma's investigational treatment for patients with transthyretin amyloid cardiomyopathy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

New EU Filings
• Source: Shutterstock

More from Product Reviews

More from Pink Sheet